The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Yasunaga, Masahiro ^a   Furuta, Masaru ^b   Ogata, Koretsugu ^b   Koga, Yoshikatsu ^a   Yamamoto, Yoshiyuki ^a   Takigahira, Misato ^a   Matsumura, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b SHIMADZU CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

ANIMAL; DISEASE MODEL; DRUG MONITORING; FEMALE; MASS SPECTROMETRY; MICROSCOPY; MOUSE; NEOPLASMS; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TISSUE DISTRIBUTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE MODELS, ANIMAL; DRUG MONITORING; FEMALE; MASS SPECTROMETRY; MICE; MICROSCOPY; NEOPLASMS; PACLITAXEL; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE DISTRIBUTION; TUMOR BURDEN;

EID: 84896538372     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03050     Document Type: Article

References (25)

1. Chin, L. & Gray, J. W. Translating insights from the cancer genome into clinical practice. Nature 452, 553-563 (2008)
2. Van Dort, M. E., Rehemtulla, A. & Ross, B. D. PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development. Curr. Comput. Aided Drug Des. 4, 46-53 (2008)
3. Garrett, M. D. &Workman, P. Discovering novel chemotherapeutic drugs for the third millennium. Eur. J. Cancer 35, 2010-2030 (1999)
4. Abramson, R. G. et al. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol. 200, 475-483 (2013)
5. Horak, C. E. et al. Biomarker analysis of neoadjuvant doxorubicin/ cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin. Cancer Res. 19, 1587-1595 (2013)
6. Waddell, T. & Cunningham, D. Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours. Br. J. Surg. 100, 5-14 (2013)
7. Cornett, D. S., Reyzer, M. L., Chaurand, P.&Caprioli, R. M. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat. Methods 4, 828-833 (2007)
8. Schwamborn, K. & Caprioli, R. M. Molecular imaging by mass spectrometry- looking beyond classical histology. Nat. Rev. Cancer 10, 639-646 (2010)
9. Castellino, S., Groseclose, M. R. & Wagner, D. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. Bioanalysis 3, 2427-2441 (2011)
10. Saito, Y. et al. Development of imaging mass spectrometry. Biol. Pharm. Bull. 35, 1417-1424 (2012)
11. Lorenz, M., Ovchinnikova, O. S., Kertesz, V. & Van Berkel, G. J. Laser microdissection and atmospheric pressure chemical ionisation mass spectrometry coupled for multimodal imaging. Rapid Commun Mass Spectrom. 27, 1429-1436 (2013)
12. Römpp, A. & Spengler, B. Mass spectrometry imaging with high resolution in mass and space. Histochem Cell Biol. 139, 759-783 (2013)
13. Rowinsky, E. K. et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is doselimiting. J. Clin. Oncol. 11, 2010-2020 (1993)
14. Hamaguchi, T. et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 92, 1240-1246 (2005)
15. Hamaguchi, T. et al. A phase I and pharmacokinetic study of NK105, a paclitaxelincorporating micellar nanoparticle formulation. Br J Cancer 97, 170-176 (2007)
16. Kato, K. et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 30, 1621-1627 (2012)
17. Matsumura, Y. & Kataoka, K. Preclinical and clinical studies of anticancer agentincorporating polymer micelles. Cancer Sci. 100, 572-579 (2009)
18. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986)
19. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6, 688-701 (2006)
20. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007)
21. Ibrahim, N. K. et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 23, 6019-26 (2005)
22. Johnson, D.H., Chang, A. Y.&Ettinger, D. S. Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience. Ann Oncol. Suppl 6, S45-50 (1994)
23. Matsumura, Y. Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev. 64, 710-719 (2012)
24. Dimou, A., Syrigos, K. N. & Saif, M. W. Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther AdvMed Oncol. 5, 271-279 (2012)
25. Harada, T. et al. Visualization of volatile substances in different organelles with an atmospheric-pressure mass microscope. Anal Chem. 81, 9153-9157 (2009)